Skip to main content
Maze Therapeutics, Inc. logo

Maze Therapeutics, Inc. — Investor Relations & Filings

Ticker · MAZE ISIN · US5787841007 US Manufacturing
Open in API
Filings indexed 139 across all filing types
Latest filing 2024-07-31 Regulatory Filings
Country US United States of America
Listing US MAZE

About Maze Therapeutics, Inc.

https://www.mazetx.com/

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company that harnesses insights from human genetics to develop novel, small molecule precision medicines. The company utilizes its proprietary Compass platform, which leverages variant functionalization, to identify and validate new therapeutic targets. Maze's strategy focuses on designing medicines that imitate the effects of rare, naturally occurring, protective genetic variants to address common diseases with significant unmet medical needs. Its pipeline is focused on advancing treatments for renal and cardio-metabolic indications, with a lead program targeting APOL1-mediated kidney disease (AMKD).

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from Maze Therapeutics, Inc. to the U.S. Securities and Exchange Commission (SEC) staff regarding comments on the company's Draft Registration Statement on Form S-1. The letter addresses SEC staff comments on disclosures, pipeline details, risk factors, licensing agreements, and accounting policies related to the company's planned initial public offering (IPO). The document references the Draft Registration Statement on Form S-1, which is a registration filing for securities offerings, not a financial report or earnings release. The content is focused on regulatory compliance and disclosure revisions in response to SEC review comments, typical of correspondence during the SEC review process for registration statements. This type of document is best classified as a Regulatory Filing (RNS) because it is a regulatory communication and does not constitute an annual report, earnings release, or other specific report types. The document length (15,000 characters) and detailed responses confirm it is not a brief announcement or certification but a substantive regulatory filing.
2024-07-31 English
Capital/Financing Update 2024
Capital/Financing Update Classification · 100% confidence The document is a confidential draft registration statement submitted to the SEC on Form S-1 by Maze Therapeutics, Inc. It is a registration statement under the Securities Act of 1933 for an initial public offering (IPO) of common stock. The document includes a preliminary prospectus with detailed information about the company, its business, risk factors, management, financial condition, and the offering terms. The presence of Form S-1 and the context of an IPO registration clearly identify this as a capital markets filing related to financing activities. This is not an annual report, earnings release, or any other type of report but a registration statement for securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the actual filing, not just an announcement or a certification.
2024-07-31 English
Regulatory Filings 2024
Regulatory Filings
2024-07-26 English
Capital/Financing Update 2024
Capital/Financing Update Classification · 100% confidence The document is a confidential draft registration statement submitted to the SEC on Form S-1 by Maze Therapeutics, Inc. It is a preliminary prospectus for an initial public offering (IPO) of common stock. The Form S-1 is a registration statement used under the Securities Act of 1933 for companies planning to go public. The document includes detailed information about the company, its business, management, risk factors, use of proceeds, and other disclosures typical of an IPO registration statement. This type of filing is not an annual report, earnings release, or any other report type listed but is a capital markets filing related to financing and securities offering. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-06-21 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.